SAVA Cassava Sciences

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

Fireside Chat on Wednesday, April 28th at 2:30PM Eastern

AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 28-29, 2021. The B. Riley Securities' Neuroscience Conference will cover key topics across neurodegeneration and neuropsychiatry disease areas with leading companies in the field.

Remi Barbier, President & CEO, will participate in a virtual Fireside Chat led by the research team at B. Riley Securities on Wednesday, April 28, 2021 at 2:30 PM – 3:00 PM Eastern time. The link for this webcast is: . An archived replay of the Fireside Chat will be available on Cassava Sciences’ website for approximately 90 days following the event.

About Cassava Sciences, Inc.

Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: .

For More Information Contact:

Eric Schoen, Chief Financial Officer



(512) 501-2450



EN
27/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cassava Sciences

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 2, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Glo...

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City. Rick Barry, President and Chief Executive ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch